11/14/2024
3:24 PM | BIOTECHNOLOGY VALUE FUND L P (Filed by)
Janux Therapeutics (Subject)
| Form SC 13G/A | |
11/08/2024
4:58 PM | Avalon Ventures XI, L.P. (Filed by)
Janux Therapeutics (Subject)
| Form SC 13D/A | |
11/07/2024
6:08 PM | CAPPS VICKIE L (Reporting)
Janux Therapeutics (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
11/07/2024
6:09 PM | Gujrathi Sheila (Reporting)
Janux Therapeutics (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
11/06/2024
3:23 PM | Janux Therapeutics (Filer)
| Form 10-Q
General form for quarterly reports under Section 13 or 15(d) | |
11/06/2024
3:07 PM | Janux Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
11/01/2024
4:05 PM | Janux Therapeutics (Subject)
Reardon Tighe (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
|
11/01/2024
4:02 PM | Janux Therapeutics (Subject)
Lichter Jay (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
11/01/2024
3:24 PM | Avalon BioVentures SPV I, L.P. (Reporting)
Janux Therapeutics (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
11/01/2024
3:30 PM | Avalon Ventures XI, L.P. (Reporting)
Janux Therapeutics (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
11/01/2024
3:17 PM | Avalon BioVentures I, LP (Reporting)
Janux Therapeutics (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
11/01/2024
3:07 PM | Janux Therapeutics (Subject)
Reardon Tighe (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
10/30/2024
6:30 PM | Campbell David Alan (Reporting)
Janux Therapeutics (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
10/28/2024
3:46 PM | Janux Therapeutics (Subject)
Reardon Tighe (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
10/25/2024
4:28 PM | Avalon Ventures XI, L.P. (Filed by)
Janux Therapeutics (Subject)
| Form SC 13D/A | |
10/25/2024
3:57 PM | Avalon Ventures XI, L.P. (Reporting)
Janux Therapeutics (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
10/25/2024
3:44 PM | Avalon BioVentures SPV I, L.P. (Reporting)
Janux Therapeutics (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
10/25/2024
3:51 PM | Avalon BioVentures I, LP (Reporting)
Janux Therapeutics (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
10/25/2024
11:37 AM | Janux Therapeutics (Subject)
Reardon Tighe (Reporting)
| Form 144/A | |
10/24/2024
4:53 PM | Janux Therapeutics (Subject)
Lichter Jay (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
10/24/2024
4:04 PM | Janux Therapeutics (Subject)
Reardon Tighe (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
10/24/2024
3:15 PM | Janux Therapeutics (Issuer)
Lichter Jay (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
10/23/2024
4:59 PM | Avalon BioVentures SPV I, L.P. (Reporting)
Janux Therapeutics (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
10/23/2024
4:38 PM | Avalon BioVentures I, LP (Reporting)
Janux Therapeutics (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
10/23/2024
4:39 PM | Janux Therapeutics (Subject)
Paradigm Biocapital Advisors LP (Filed by)
| Form SC 13G | |
10/23/2024
4:07 PM | Avalon Ventures XI, L.P. (Reporting)
Janux Therapeutics (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
10/23/2024
3:36 PM | Janux Therapeutics (Subject)
Reardon Tighe (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
10/22/2024
3:20 PM | Janux Therapeutics (Issuer)
Kolchinsky Peter (Reporting)
RA Capital Healthcare Fund LP (Reporting)
RA CAPITAL MANAGEMENT, L.P. (Reporting)
RA Capital Nexus Fund II, L.P. (Reporting)
Shah Rajeev M. (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
10/22/2024
3:16 PM | Avalon Ventures XI, L.P. (Filed by)
Janux Therapeutics (Subject)
| Form SC 13D/A | |
10/22/2024
3:17 PM | Janux Therapeutics (Subject)
RA CAPITAL MANAGEMENT, L.P. (Filed by)
| Form SC 13D/A | |
10/21/2024
3:43 PM | Janux Therapeutics (Subject)
Reardon Tighe (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
10/21/2024
3:25 PM | Janux Therapeutics (Subject)
Reardon Tighe (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
10/21/2024
12:39 PM | Janux Therapeutics (Subject)
Lichter Jay (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
10/18/2024
5:51 PM | Avalon BioVentures I, LP (Reporting)
Avalon BioVentures SPV I, L.P. (Reporting)
Avalon Ventures XI, L.P. (Reporting)
Janux Therapeutics (Issuer)
Lichter Jay (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
10/18/2024
3:57 PM | Avalon Ventures XI, L.P. (Reporting)
Janux Therapeutics (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
10/18/2024
3:39 PM | Avalon BioVentures SPV I, L.P. (Reporting)
Janux Therapeutics (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
10/18/2024
3:48 PM | Avalon BioVentures I, LP (Reporting)
Janux Therapeutics (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
10/17/2024
4:06 PM | Janux Therapeutics (Subject)
Reardon Tighe (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
10/17/2024
3:24 PM | Janux Therapeutics (Subject)
Lichter Jay (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
10/17/2024
3:18 PM | Janux Therapeutics (Subject)
Reardon Tighe (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
10/16/2024
5:14 PM | Janux Therapeutics (Subject)
Reardon Tighe (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
The Tesla Trade Is Back In Business (Ad) If you held shares of Tesla throughout 2024, you know It’s been a year of extreme highs and lows…
But according to our one expert, new yearly highs are on the horizon…
In his words, Tesla is building momentum like in 2020, especially as Trump supports the EV maker.
Which is why we’re emailing you now…
You see, most people will simply buy shares of Tesla ahead of the election…
But as they say “There is more than one way to skin a cat”
In fact, we’ve found another way to play shares of Tesla. Discover how to trade Tesla, simply follow this link here. |
10/16/2024
4:35 PM | Avalon BioVentures I, LP (Reporting)
Janux Therapeutics (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
10/16/2024
4:28 PM | Janux Therapeutics (Subject)
Lichter Jay (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
10/16/2024
4:25 PM | Avalon BioVentures SPV I, L.P. (Reporting)
Janux Therapeutics (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
10/16/2024
4:17 PM | Avalon Ventures XI, L.P. (Reporting)
Janux Therapeutics (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
10/16/2024
4:10 PM | Janux Therapeutics (Subject)
Reardon Tighe (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
09/30/2024
7:49 PM | Avalon BioVentures I, LP (Reporting)
Avalon BioVentures SPV I, L.P. (Reporting)
Avalon Ventures XI, L.P. (Reporting)
Janux Therapeutics (Issuer)
Lichter Jay (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
09/30/2024
4:29 PM | Janux Therapeutics (Subject)
Reardon Tighe (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
09/30/2024
4:34 PM | Janux Therapeutics (Subject)
Lichter Jay (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
09/27/2024
6:30 PM | Campbell David Alan (Reporting)
Janux Therapeutics (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
09/27/2024
6:31 PM | DiRaimondo Thomas (Reporting)
Janux Therapeutics (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
09/27/2024
6:32 PM | Janux Therapeutics (Issuer)
Meyer Andrew Hollman (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
09/27/2024
5:31 PM | Janux Therapeutics (Subject)
Reardon Tighe (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
09/27/2024
4:05 PM | Avalon BioVentures SPV I, L.P. (Reporting)
Janux Therapeutics (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
09/27/2024
3:51 PM | Avalon Ventures XI, L.P. (Reporting)
Janux Therapeutics (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
09/27/2024
3:51 PM | Avalon BioVentures I, LP (Reporting)
Janux Therapeutics (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
09/27/2024
3:54 PM | Janux Therapeutics (Subject)
Lichter Jay (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
09/27/2024
3:18 PM | Janux Therapeutics (Subject)
Reardon Tighe (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
09/27/2024
3:01 PM | Janux Therapeutics (Subject)
Meyer Andrew Hollman (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
09/27/2024
3:05 PM | Campbell David Alan (Reporting)
Janux Therapeutics (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
09/26/2024
4:57 PM | Avalon Ventures XI, L.P. (Reporting)
Janux Therapeutics (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
09/26/2024
4:35 PM | Avalon BioVentures SPV I, L.P. (Reporting)
Janux Therapeutics (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
09/26/2024
4:13 PM | Avalon BioVentures I, LP (Reporting)
Janux Therapeutics (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
09/16/2024
8:35 PM | Janux Therapeutics (Subject)
RA CAPITAL MANAGEMENT, L.P. (Filed by)
| Form SC 13D/A | |
09/16/2024
8:41 PM | Avalon Ventures XI, L.P. (Filed by)
Janux Therapeutics (Subject)
| Form SC 13D/A | |
09/13/2024
4:01 PM | Janux Therapeutics (Subject)
Lichter Jay (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
09/12/2024
8:18 PM | Avalon BioVentures I, LP (Reporting)
Janux Therapeutics (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
09/12/2024
7:54 PM | Avalon Ventures XI, L.P. (Reporting)
Janux Therapeutics (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
09/12/2024
8:07 PM | Avalon BioVentures SPV I, L.P. (Reporting)
Janux Therapeutics (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
09/12/2024
7:42 PM | Avalon BioVentures I, LP (Reporting)
Avalon BioVentures SPV I, L.P. (Reporting)
Avalon Ventures XI, L.P. (Reporting)
Janux Therapeutics (Issuer)
Lichter Jay (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
09/12/2024
5:23 PM | Janux Therapeutics (Subject)
Reardon Tighe (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
09/12/2024
3:51 PM | Janux Therapeutics (Subject)
Reardon Tighe (Reporting)
| Form 144/A | |
09/11/2024
10:20 AM | Janux Therapeutics (Subject)
Reardon Tighe (Reporting)
| Form 144/A | |
09/10/2024
5:26 PM | Avalon BioVentures SPV I, L.P. (Reporting)
Janux Therapeutics (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
09/10/2024
5:32 PM | Avalon BioVentures I, LP (Reporting)
Janux Therapeutics (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
09/10/2024
5:22 PM | Avalon Ventures XI, L.P. (Reporting)
Janux Therapeutics (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
09/10/2024
4:51 PM | Janux Therapeutics (Subject)
Reardon Tighe (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
09/10/2024
4:02 PM | Avalon BioVentures I, LP (Reporting)
Avalon BioVentures SPV I, L.P. (Reporting)
Avalon Ventures XI, L.P. (Reporting)
Janux Therapeutics (Issuer)
Lichter Jay (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
09/10/2024
3:13 PM | Janux Therapeutics (Subject)
Reardon Tighe (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
09/09/2024
5:03 PM | Janux Therapeutics (Subject)
Reardon Tighe (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
09/09/2024
5:09 PM | Janux Therapeutics (Subject)
Lichter Jay (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
09/09/2024
2:35 PM | Janux Therapeutics (Subject)
Reardon Tighe (Reporting)
| Form 144/A | |
09/09/2024
1:28 PM | Janux Therapeutics (Subject)
Reardon Tighe (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
09/06/2024
6:11 PM | Avalon Ventures XI, L.P. (Reporting)
Janux Therapeutics (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
09/06/2024
6:14 PM | Avalon BioVentures SPV I, L.P. (Reporting)
Janux Therapeutics (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
09/06/2024
6:17 PM | Avalon BioVentures I, LP (Reporting)
Janux Therapeutics (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
08/09/2024
6:06 PM | Dobek Maria (Reporting)
Janux Therapeutics (Issuer)
| Form 3
Initial statement of beneficial ownership of securities | |
08/07/2024
3:20 PM | Janux Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
08/07/2024
3:28 PM | Janux Therapeutics (Filer)
| Form 10-Q
General form for quarterly reports under Section 13 or 15(d) | |
07/24/2024
7:00 PM | Hernday Natasha (Reporting)
Janux Therapeutics (Issuer)
| Form 4/A | |
07/24/2024
7:00 PM | DOBMEIER ERIC (Reporting)
Janux Therapeutics (Issuer)
| Form 4/A | |
Strange: Why is Amazon suddenly yielding 39.70%? (Ad) Something big is happening with Amazon stock…
While most investors collect ZERO dividends from Amazon…
A small group just discovered a "backdoor" way to collect yields up to 39.70%! Click here to see this breakthrough before everyone else → |
07/22/2024
7:01 PM | Hernday Natasha (Reporting)
Janux Therapeutics (Issuer)
| Form 3
Initial statement of beneficial ownership of securities | |
07/22/2024
7:01 PM | DOBMEIER ERIC (Reporting)
Janux Therapeutics (Issuer)
| Form 3
Initial statement of beneficial ownership of securities | |
07/22/2024
7:03 PM | Hernday Natasha (Reporting)
Janux Therapeutics (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
07/22/2024
7:04 PM | DOBMEIER ERIC (Reporting)
Janux Therapeutics (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
07/22/2024
4:00 PM | Janux Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
06/28/2024
3:30 PM | CAPPS VICKIE L (Reporting)
Janux Therapeutics (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
06/28/2024
3:30 PM | Janux Therapeutics (Issuer)
Simson Jake (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
06/28/2024
3:30 PM | Barrett Ronald W (Reporting)
Janux Therapeutics (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
06/28/2024
3:30 PM | Gujrathi Sheila (Reporting)
Janux Therapeutics (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
Free JANX Stock Alerts